ASX dividend stocks remain a favourite for income-focused investors looking to generate steady passive income while still participating in long-term capital growth.

That income stream can also act as a useful buffer during periods of share market volatility, which remains a key theme right now as markets continue to fluctuate.

With that in mind, two of the ASX’s most established defensive dividend payers stand out today. They offer reliable cash flows, essential infrastructure exposure, and long track records of shareholder returns.

Let’s take a closer look.

APA Group (ASX: APA)

APA Group is one of Australia’s most important energy infrastructure businesses.

It owns and operates a vast portfolio of gas, electricity, solar, and wind assets across the country, including pipelines, storage facilities, and gas-fired power stations. In fact, APA transports more than half of Australia’s natural gas through its network.

That scale and essential service exposure make APA a classic defensive ASX dividend stock. Demand for energy infrastructure remains relatively stable through economic cycles, and much of APA’s revenue is underpinned by long-term, often inflation-linked contracts.

This structure helps smooth earnings and supports consistent income for shareholders.

APA has paid regular distributions for close to two decades, reflecting the reliability of its infrastructure-based earnings model.

The company typically pays two distributions per year and most recently paid an interim distribution of 27.5 cents per security. It is guiding to a full-year FY26 distribution of 58 cents per security.

At current levels, this equates to a forward yield of around 5.6%, making it an attractive option for income investors seeking stability and yield.

Transurban Group (ASX: TCL)

Transurban Group is another high-quality defensive dividend stock that operates one of the largest urban toll road networks in the world.

The company owns and operates 22 toll road assets across Australia, the US, and Canada, including major motorways, tunnels, and bridges.

Its appeal lies in the essential nature of its assets. Even during economic downturns, people still need to travel for work, freight needs to move, and cities continue to function. That helps ensure relatively stable traffic volumes and resilient cash flow.

The ASX dividend stock also benefits from inflation-linked pricing mechanisms on many of its roads, allowing it to increase tolls annually in line with inflation. That provides a natural hedge in higher price environments.

The company paid an interim distribution of 34 cents per share in February and has guided to a full-year FY26 distribution of 69 cents per share.

At current levels, that represents a forward yield of approximately 4.6%, reinforcing its appeal as a dependable income generator.

Foolish takeaway

Together, APA Group and Transurban offer investors exposure to essential infrastructure assets with long-term contracted or regulated revenue streams.

They may not be the most exciting growth stories on the ASX, but for investors seeking steady income and defensive characteristics, these ASX dividend stocks remain two of the market’s most reliable dividend payers.

The post $5,000 buys 194 shares in these 2 top ASX dividend stocks appeared first on The Motley Fool Australia.

More reading

• How much do I need in my superannuation to get $1000 per week in passive income?
• Want passive income? These 3 ASX dividend stocks could deliver
• Transurban Group declares FY26 distribution; announces AGM date
• How I’d build $50,000 of ASX passive income
• 3 ASX dividend shares to buy and hold for years of income

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group. The Motley Fool Australia has positions in and has recommended Apa Group and Transurban Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Some ASX shares spend long periods in the market’s bad books.

That can be frustrating for existing shareholders, but it can also create opportunities for patient investors. When expectations are already low, a business does not need perfection to improve the investment case. It may only need steadier execution, better confidence, or a clearer path to growth.

Here are two ASX shares I would consider buying before sentiment improves.

CSL Ltd (ASX: CSL)

CSL is one share I think investors may come back to over time.

The healthcare giant has been through a difficult period, and confidence is lower than it once was. But I still think the core business has plenty of value.

CSL operates in markets that are difficult to enter and require deep expertise, global scale, regulatory experience, and long relationships with healthcare providers. Plasma therapies, vaccines, and other specialist healthcare products are not areas where new competitors can simply arrive and quickly take market share.

What interests me now is the reset in expectations. CSL no longer needs to be viewed as a perfect compounder to be a worthwhile investment. A period of steadier margins, better execution, and clearer earnings growth could be enough to change the conversation.

The business still needs to deliver, of course. But I think the market may be underestimating how valuable CSL’s global healthcare infrastructure remains.

Zip Co Ltd (ASX: ZIP)

Zip is a very different idea. This is a higher-risk growth share, but I think it has become more interesting as the business has matured.

The old buy now, pay later excitement has faded. That may be a good thing. Zip is now being judged more on earnings, credit quality, operating discipline, and whether it can build a sustainable payments business.

I like that shift. A company that can grow while controlling risk has a much better chance of creating long-term value than one chasing volume at any cost. Zip still needs to prove that its model can keep scaling profitably, especially in large markets such as the United States.

But if management keeps improving credit settings, customer quality, and operating leverage, I think the upside could be meaningful.

Zip remains speculative compared with a blue-chip share. Still, I think it is the kind of stock that can move quickly if the market starts to believe the earnings story has changed.

Foolish takeaway

Buying before sentiment improves is uncomfortable by nature.

The easier moment usually comes later, after the share price has already started to recover and the story sounds cleaner. That is why I think shares like CSL and Zip are worth watching closely now.

Both businesses have something to prove, but both also have a credible path to becoming more valuable if execution improves. That is the kind of setup I like when looking for opportunities.

The post Why I’d buy CSL and Zip shares before they recover appeared first on The Motley Fool Australia.

More reading

• New to ASX shares? Avoid these 3 beginner mistakes
• Down 54%: What should I do with my CSL shares now?
• Is this broker right about CSL shares?
• 3 cheap ASX shares that could be hiding in plain sight
• Why A2 Milk, Calix, CSL, and Ioneer shares are charging higher today

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This ASX healthcare stock has become one of the biggest success stories on the ASX.

4DMedical Ltd (ASX: 4DX) has surged 26% over the past five trading days, climbed 37% in the past month, and rocketed an astonishing 1,900% over the past year.

The remarkable rally has now caught the attention of one of the world’s largest investment firms. Let’s take a look at who it is and why it has purchased millions of 4DMedical shares.

Sizeable new stake

According to an ASX update released on Wednesday, JP Morgan Chase & Co. (NYSE: JPM) has acquired more than 31 million shares in 4DMedical, giving it a stake of approximately 6.3% in the company.

The move suggests the investment giant sees potential in a business that is rapidly emerging as a major player in healthcare imaging technology.

It’s not hard to see why investor interest in the ASX healthcare stock has surged.

Intersection AI and medical imaging

4DMedical develops advanced respiratory imaging technology that allows clinicians to assess lung function in ways traditional imaging methods cannot.

Its proprietary software and artificial intelligence tools create detailed functional images of the lungs, helping doctors diagnose and manage respiratory conditions more effectively.

As healthcare providers increasingly adopt AI-powered diagnostic tools, 4DMedical is positioning itself at the intersection of two powerful long-term growth trends: medical imaging and artificial intelligence.

Recent company announcements have only strengthened that investment case.

Expanding globally

One of the company’s biggest recent moves was its acquisition of Austrian AI imaging company Contextflow.

The deal immediately expands 4DMedical’s European footprint and adds lung cancer screening capabilities. It also provides access to existing reimbursement arrangements in Germany.

Management of the ASX healthcare stock believes the acquisition could increase the company’s addressable market by around 50%, significantly expanding its long-term growth opportunity.

For investors, it represents another step in transforming 4DMedical from an emerging Australian healthcare company into a global imaging technology business.

Making progress in the US

The company has also been gaining traction in the world’s largest healthcare market.

Recently, 4DMedical announced a major agreement with SimonMed. This is one of the largest outpatient imaging providers in the US, with more than 170 imaging centres.

The partnership supports the rollout of the company’s CT:VQ lung imaging technology. It provides access to a large network of healthcare providers and potential patients.

Earlier this month, management also launched its CLEAR clinical program targeting acute pulmonary embolism.

Importantly, the ASX healthcare stock believes this initiative could expand the US addressable market for CT:VQ to approximately US$3 billion. This highlights the scale of the opportunity if adoption continues to grow.

Raised expectations

Despite the excitement, investors should remember that expectations are now much higher than they were a year ago.

After a 1,900% gain, the market is increasingly focused on execution. The ASX healthcare stock must continue converting clinical success into commercial adoption. It also needs to grow revenue, expand reimbursement coverage, and successfully integrate its European operations.

Any slowdown in adoption or commercial progress could lead to heightened volatility.

Even so, JP Morgan’s new stake suggests at least one major institutional investor believes the growth story still has room to run. For shareholders, that vote of confidence is unlikely to go unnoticed.

The post This ASX healthcare stock is up 1,900%. One top fundie wants more appeared first on The Motley Fool Australia.

More reading

• Up 1,700% and more, what’s next for these ASX 200 shares?
• Here are the top 10 ASX 200 shares today
• Here are the 10 most shorted ASX shares
• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?
• Here are the top 10 ASX 200 shares today

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.